Spironolactone for HFpEF with Pulmonary Hypertension
In patients with HFpEF and pulmonary hypertension, spironolactone should be initiated at 25 mg daily if the patient has elevated natriuretic peptides (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL), serum potassium <5.0 mmol/L, and eGFR ≥30 mL/min, with close monitoring of potassium and creatinine. 1, 2, 3
Evidence Base and Patient Selection
The most recent 2026 ACC Expert Consensus 2 and 2026 ESC Guidelines 3 recommend mineralocorticoid receptor antagonists (MRAs) for all symptomatic HF patients regardless of ejection fraction, based on their ability to reduce heart failure hospitalizations. However, the evidence for spironolactone specifically in HFpEF comes primarily from the TOPCAT trial 4, which showed mixed results.
Key patient selection criteria:
- LVEF ≥40-45% 1, 2, 5
- NYHA class II-IV symptoms 1, 5
- Either elevated natriuretic peptides (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) OR hospitalization for HF within the past year 1, 2
- Serum potassium <5.0 mmol/L 1, 2, 5
- eGFR ≥30 mL/min (or creatinine <221 μmol/L) 1, 3
Critical caveat: The benefit of spironolactone in HFpEF is most evident in patients with elevated natriuretic peptides. In the TOPCAT trial, patients enrolled based on elevated BNP/NT-proBNP had a 35% reduction in the primary endpoint (HR 0.65,95% CI 0.49-0.87), while those enrolled based on prior hospitalization alone showed no benefit 1. This makes natriuretic peptide elevation a crucial selection criterion.
Initiation Protocol
Starting dose: 25 mg once daily 6, 7, 2, 5
Pre-initiation requirements:
- Check baseline serum potassium and creatinine 6
- Ensure patient is on appropriate background therapy (ACE inhibitor/ARB or ARNI, beta-blocker if indicated) 6
- Verify no contraindications (see below)
Initial monitoring schedule: 6, 1, 6
- Recheck potassium and creatinine at 1 week after initiation
- Recheck again at 4 weeks
- Then at 4 months
- Subsequently every 3-6 months or whenever clinically indicated
The 2015 Canadian guidelines 1 specifically recommend this "1 week, 4 weeks, 4 months" monitoring schedule, which is more practical than older protocols.
Dose Titration
Target dose: 25-50 mg once daily 7, 2, 5
After 4-8 weeks, if the patient is tolerating the initial 25 mg dose without hyperkalemia or worsening renal function, consider increasing to 50 mg daily 6. However, the mean dose achieved in the TOPCAT trial was only 25 mg daily 5, and recent evidence suggests that doses ≤40 mg may provide the best balance of efficacy and safety in HFpEF patients with comorbidities 8.
Recheck potassium and creatinine 1 week and 4 weeks after any dose increase 6.
Monitoring and Management of Adverse Effects
Hyperkalemia Management 6, 5
Potassium 5.5-6.0 mmol/L:
- Halve the dose (e.g., 25 mg every other day)
- Recheck potassium closely
- Consider potassium binders if needed to maintain therapy
Potassium ≥6.0 mmol/L:
- Stop spironolactone immediately
- Monitor potassium closely
- Treat hyperkalemia as needed
- May cautiously restart at lower dose once potassium normalizes
Important note: Hyperkalemia occurred in 18.7% of spironolactone-treated patients vs. 9.1% with placebo in TOPCAT 4, but with close monitoring, serious adverse events were rare. The risk is amplified in patients with lower eGFR 9, so more frequent monitoring is essential in those with baseline renal impairment.
Worsening Renal Function 6
Creatinine rises to 220 μmol/L (2.5 mg/dL):
- Halve the dose
- Monitor closely
Creatinine rises to ≥310 μmol/L (3.5 mg/dL):
- Stop spironolactone immediately
- Monitor closely and treat as needed
An increase in creatinine up to 30% may be acceptable if it stabilizes 10, but requires closer long-term monitoring.
Other Adverse Effects 5
Gynecomastia: Occurs in approximately 9% of male patients 6, usually reversible upon discontinuation. Consider switching to eplerenone or finerenone if this occurs, though these alternatives have different evidence profiles in HFpEF.
Hypotension: Monitor blood pressure; may need to adjust timing or doses of other antihypertensive medications 10.
Contraindications 6, 5
Absolute contraindications:
- Serum potassium ≥5.0 mmol/L at baseline
- eGFR <30 mL/min or creatinine >221 μmol/L (2.5 mg/dL)
- Concurrent use of potassium supplements or potassium-sparing diuretics
- Concurrent use of strong CYP3A4 inhibitors
- Triple therapy with ACE inhibitor + ARB + spironolactone (unless in specialized HF clinic with very close monitoring) 10
Special Considerations for Pulmonary Hypertension
While the evidence specifically addresses HFpEF, pulmonary hypertension is common in this population and does not change the approach to spironolactone initiation. The key is ensuring the patient meets HFpEF criteria with elevated filling pressures rather than isolated pulmonary vascular disease.
Monitor for:
- Volume status changes that might affect pulmonary pressures
- Right ventricular function deterioration
- Signs of worsening congestion despite diuretic therapy
Practical Algorithm
- Confirm eligibility: HFpEF (EF ≥40%), elevated natriuretic peptides, K+ <5.0, eGFR ≥30
- Start 25 mg daily
- Check labs at 1 week: If K+ <5.5 and creatinine stable, continue
- Check labs at 4 weeks: If K+ <5.5 and creatinine stable, continue
- Consider uptitration at 4-8 weeks to 50 mg if well-tolerated (though 25 mg may be sufficient)
- Check labs 1 week after uptitration
- Long-term monitoring: Every 3-6 months, or more frequently if eGFR <45 mL/min
Common pitfall: Combining spironolactone with ACE inhibitor and ARB increases hyperkalemia risk substantially 10. If the patient is on both ACE inhibitor and ARB, consider discontinuing one before adding spironolactone, or ensure very close monitoring in a specialized clinic setting.